TY - JOUR
T1 - Sustained Effectiveness of an Advanced Hybrid Closed Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study
AU - Passanisi, Stefano
AU - Salzano, Giuseppina
AU - Bombaci, Bruno
AU - Minuto, Nicola
AU - Bassi, Marta
AU - Bonfanti, Riccardo
AU - Scialabba, Francesco
AU - Mozzillo, Enza
AU - Di Candia, Francesca
AU - Monti, Sara
AU - Graziani, Vanna
AU - Maffeis, Claudio
AU - Piona, Claudia Anita
AU - Arnaldi, Claudia
AU - Tosini, Davide
AU - Felappi, Barbara
AU - Roppolo, Rosalia
AU - Zanfardino, Angela
AU - Delvecchio, Maurizio
AU - Lo Presti, Donatella
AU - Calzi, Elena
AU - Ripoli, Carlo
AU - Franceschi, Roberto
AU - Reinstadler, Petra
AU - RABBONE, IVANA
AU - Maltoni, Giulio
AU - Alibrandi, Angela
AU - Zucchini, Stefano
AU - Marigliano, Marco
AU - Lombardo, Fortunato
N1 - Publisher Copyright:
© 2024 by the American Diabetes Association.
PY - 2024
Y1 - 2024
N2 - Objective: To investigate glucose metrics and identify potential predictors of the achievement of glycemic outcomes in children and adolescents during their first 12 months of MiniMed 780G use. Research design and methods: This multicenter, longitudinal, real-world study recruited 368 children and adolescents with type 1 diabetes (T1D) starting SmartGuard technology between June 2020 and June 2022. Ambulatory glucose profile data were collected during a 15-day run-in period (baseline), 2 weeks after automatic mode activation, and every 3 months. The influence of covariates on glycemic outcomes after 1 year of MiniMed 780G use was assessed. Results: After 15 days of automatic mode use, all glucose metrics improved compared with baseline (P < 0.001), except for time below range (P = 0.113) and coefficient of variation (P = 0.330). After 1 year, time in range (TIR) remained significantly higher than at baseline (75.3% vs. 62.8%, P < 0.001). The mean glycated hemoglobin (HbA1c) over the study duration was lower than the previous year (6.9 ± 0.6% vs. 7.4 ± 0.9%, P < 0.001). Time spent in tight range (70-140 mg/dL) was 51.1%, and the glycemia risk index was 27.6. Higher TIR levels were associated with a reduced number of automatic correction boluses (P < 0.001), fewer SmartGuard exits (P = 0.021), and longer time in automatic mode (P = 0.030). Individuals with baseline HbA1c >8% showed more relevant improvement in TIR levels (from 54.3 to 72.3%). Conclusions: Our study highlights the sustained effectiveness of MiniMed 780G among youths with T1D. Findings suggest that even children and adolescents with low therapeutic engagement may benefit from SmartGuard technology.
AB - Objective: To investigate glucose metrics and identify potential predictors of the achievement of glycemic outcomes in children and adolescents during their first 12 months of MiniMed 780G use. Research design and methods: This multicenter, longitudinal, real-world study recruited 368 children and adolescents with type 1 diabetes (T1D) starting SmartGuard technology between June 2020 and June 2022. Ambulatory glucose profile data were collected during a 15-day run-in period (baseline), 2 weeks after automatic mode activation, and every 3 months. The influence of covariates on glycemic outcomes after 1 year of MiniMed 780G use was assessed. Results: After 15 days of automatic mode use, all glucose metrics improved compared with baseline (P < 0.001), except for time below range (P = 0.113) and coefficient of variation (P = 0.330). After 1 year, time in range (TIR) remained significantly higher than at baseline (75.3% vs. 62.8%, P < 0.001). The mean glycated hemoglobin (HbA1c) over the study duration was lower than the previous year (6.9 ± 0.6% vs. 7.4 ± 0.9%, P < 0.001). Time spent in tight range (70-140 mg/dL) was 51.1%, and the glycemia risk index was 27.6. Higher TIR levels were associated with a reduced number of automatic correction boluses (P < 0.001), fewer SmartGuard exits (P = 0.021), and longer time in automatic mode (P = 0.030). Individuals with baseline HbA1c >8% showed more relevant improvement in TIR levels (from 54.3 to 72.3%). Conclusions: Our study highlights the sustained effectiveness of MiniMed 780G among youths with T1D. Findings suggest that even children and adolescents with low therapeutic engagement may benefit from SmartGuard technology.
UR - https://iris.uniupo.it/handle/11579/177402
U2 - 10.2337/dc23-2311
DO - 10.2337/dc23-2311
M3 - Article
SN - 1935-5548
VL - 47
SP - 1084
EP - 1091
JO - Diabetes Care
JF - Diabetes Care
IS - 6
ER -